Emergent BioSolutions | EBS - Despesas Operacionais





Despesas Operacionais Alterar Data
Acadia Pharmaceuticals USD 272.68M 6.08M 2026-03
Akebia Therapeutics USD 63.08M 8.26M 2025-12
ALKERMES USD 1.75B 1.43B 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Amarin USD 51.48M 113K 2025-12
ANI Pharmaceuticals USD 562.3M 344.37M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Coherus Biosciences USD 51.83M 2.48M 2025-12
Emergent BioSolutions USD 555.9M 242.7M 2023-06
Exelixis USD 359.47M 3.28M 2026-03
Glaxosmithkline GBP 9.17B 1.4B 2025-12
Heron Therapeutics USD 40.55M 1.46M 2025-12
Ionis Pharmaceuticals USD 364M 54M 2026-03
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
Lexicon Pharmaceuticals USD 20.27M 6.1M 2025-12
Lonza CHF 2.9B 184M 2025-06
Merck USD 18.17B 8.01B 2026-03
Moderna USD 1.78B 242M 2026-03
Myriad Genetics USD 212.8M 16.2M 2025-12
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Neurocrine Biosciences USD 599.9M 22.3M 2026-03
Pacira USD 172.75M 20.93M 2026-03
Pfizer USD 90.1B 77.19B 2026-03
PTC Therapeutics USD 226.66M 19.64M 2026-03
Sanofi EUR 9.31B 1.2B 2026-03
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
United Therapeutics USD 5.9B 5.1B 2026-03
Vanda Pharmaceuticals USD -1.14B 1.6B 2025-12
Xoma USD 22.84M 1.67M 2024-09